ResearcherInstituto Maimónides de Investigación Biomédica de CórdobaActive in the last 2 years
Antonio Rodríguez‐Ariza
Matched on ORCID iD 0000-0001-5304-5745; OpenAlex author ID A5058755562. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 7
- NR3C1, LAX1, and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metastatic Pancreatic Cancer. Co-author DOI 10.1002/mco2.70682↗
- Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance. Co-author DOI 10.1016/j.critrevonc.2025.104807↗
- Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. Co-author DOI 10.1016/j.ctrv.2024.102719↗
- Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer. Co-author DOI 10.1186/s13148-023-01535-4↗
- Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. Last author DOI 10.1186/s40364-023-00528-y↗
- The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreat… Co-author DOI 10.3390/cancers13061210↗
- Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers12071754↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marta Toledano‐Fonseca · 7 shared papers, 2020–2026 · strength 1.46
- Paper NR3C1, LAX1, and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metas… DOI 10.1002/mco2.70682↗
- Paper Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance. DOI 10.1016/j.critrevonc.2025.104807↗
- Paper Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. DOI 10.1186/s40364-023-00528-y↗
- Enrique Aranda · 7 shared papers, 2020–2026 · strength 1.46
- Paper NR3C1, LAX1, and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metas… DOI 10.1002/mco2.70682↗
- Paper Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance. DOI 10.1016/j.critrevonc.2025.104807↗
- Paper Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. DOI 10.1186/s40364-023-00528-y↗
- Maria Victoria García‐Ortiz · 6 shared papers, 2021–2026 · strength 1.35
- Paper NR3C1, LAX1, and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metas… DOI 10.1002/mco2.70682↗
- Paper Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance. DOI 10.1016/j.critrevonc.2025.104807↗
- Paper Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. DOI 10.1186/s40364-023-00528-y↗
- Pablo Cano-Ramírez · 3 shared papers, 2023–2026 · strength 0.73
- Paper NR3C1, LAX1, and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metas… DOI 10.1002/mco2.70682↗
- Paper Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. DOI 10.1186/s40364-023-00528-y↗
- Paper Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer. DOI 10.1186/s13148-023-01535-4↗
- Elena Brozos-Vázquez · 2 shared papers, 2024–2025 · strength 0.50
- Rafael López‐López · 2 shared papers, 2024–2025 · strength 0.50
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.